Skip to main content

NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.

Publication ,  Journal Article
Flaig, TW; Spiess, PE; Abern, M; Agarwal, N; Bangs, R; Boorjian, SA; Buyyounouski, MK; Chan, K; Chang, S; Friedlander, T; Greenberg, RE ...
Published in: J Natl Compr Canc Netw
August 2022

The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non-muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non-muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody-drug conjugates for metastatic bladder cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

August 2022

Volume

20

Issue

8

Start / End Page

866 / 878

Location

United States

Related Subject Headings

  • Urinary Bladder Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Recurrence, Local
  • Neoplasm Invasiveness
  • Male
  • Humans
  • Carcinoma, Transitional Cell
  • Administration, Intravesical
  • 4203 Health services and systems
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Flaig, T. W., Spiess, P. E., Abern, M., Agarwal, N., Bangs, R., Boorjian, S. A., … Gurski, L. A. (2022). NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw, 20(8), 866–878. https://doi.org/10.6004/jnccn.2022.0041
Flaig, Thomas W., Philippe E. Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, et al. “NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.J Natl Compr Canc Netw 20, no. 8 (August 2022): 866–78. https://doi.org/10.6004/jnccn.2022.0041.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, et al. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 Aug;20(8):866–78.
Flaig, Thomas W., et al. “NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.J Natl Compr Canc Netw, vol. 20, no. 8, Aug. 2022, pp. 866–78. Pubmed, doi:10.6004/jnccn.2022.0041.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 Aug;20(8):866–878.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

August 2022

Volume

20

Issue

8

Start / End Page

866 / 878

Location

United States

Related Subject Headings

  • Urinary Bladder Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Recurrence, Local
  • Neoplasm Invasiveness
  • Male
  • Humans
  • Carcinoma, Transitional Cell
  • Administration, Intravesical
  • 4203 Health services and systems